Short Courses

3D Cell-Based Assays for Drug De-Risking

Saturday, February 3
8:00 AM - 3:15 PM
Location: 2

Cell-based in vitro assays are used throughout the drug discovery and development chain, allowing for high throughput efficacy but also mechanistic-based toxicity testing. A big challenge however is the translation of in vitro assays towards the in vivo outcome. Physiological relevance is a key parameter to improve the predictive power of cell-based assays. The better we can reflect tissue architecture, composition and function the more predictive an in vitro assay will become. The 3D course covers advances in 3D cell culture technologies, assays and their use in drug discovery and development.

Additional fees apply. Visit for more information.

Patrick Guye

Chief Scientific Officer
InSphero AG

The Chief Scientific Officer at InSphero AG, Dr. Guye possesses extensive experience in life sciences, engineering, business innovation & development, operations and new ventures consulting. He has held leadership positions in industry (Sanofi) and academia (Massachusetts Institute of Technology, Princeton University) with a focus on cell therapy, 3D cellular models/organoids, synthetic biology, human stem cells, biologics and small molecules development, and precision genomic engineering. Patrick earned his PhD in Molecular Infection Biology from the University of Basel.


Send Email for Patrick Guye

Anthony Essex

Chief Scientific Officer
Phenovista Biosciences


Send Email for Anthony Essex

Olivier Frey

Group Lead Technology & Platforms
InSphero AG

Olivier Frey leads the Technology & Platforms group at InSphero AG, Switzerland. InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. Before joining InSphero, Olivier Frey, was group leader at the Department of Biosystems Science and Engineering of ETH Zurich, Switzerland. In the Bio Engineering Laboratory of Prof. Andreas Hierlemann he was responsible for the development of integrated microfluidic systems for single cell handling and 3D tissue cultures. Included are in particular multi-tissue systems, or so-called “Body-on-a-Chip” configurations based on 3D microtissue spheroids for microtissue culturing, analysis and interaction. Olivier Frey received his Diploma in Mechanical Engineering from ETH Zurich and his Doctoral degree in Micro Engineering from EPF Lausanne, Switzerland, Laboratory (SAMLAB) of Prof. Nico de Rooij.


Send Email for Olivier Frey

Alex Ng

Graduate Student
Harvard Medical School


Send Email for Alex Ng

Terry Riss

Global Strategic Manager, Cell Health
Promega Corporation

Dr. Riss received a PhD in Cell Biology from the University of Illinois in 1978 in the field of mammary gland biology. He did postdoctoral work at the University of Texas Medical School in Houston purifying growth factors involved with breast cancer and developing serum-free media formulations to implement bioassays. Dr. Riss moved to the Biotechnology division of Schering Plough in 1988 to develop interleukin/cytokine bioassays to support investigational new drug filings. Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and has held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Global Strategic Marketing Manager, Cell Health involved in outreach educational training activities. Dr. Riss has participated in several NIH study sections reviewing HTS grants and is co-editor of the cell culture assays section of the Assay Guidance Manual hosted by NIH.


Send Email for Terry Riss


3D Cell-Based Assays for Drug De-Risking

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for 3D Cell-Based Assays for Drug De-Risking